Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

This study is designed to assess the safety of Mylotarg therapy in routine practice.

Completed

Looking for future studies?

Key information

Conditions

Acute Myeloid Leukemia Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasms Neoplasms by Histologic Type

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Tucson, Arizona, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Treated by Mylotarg
Provide ICF

Treatment and study plan

Mylotarg

Drug

Sponsors and collaborators

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Industry

Registry information

Official study title

Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Important dates

Study start: 2001
First posted: Sep 12, 2005
Registry last updated: Mar 15, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed